Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.
The AeroVax study, supported by $8M in funding from the Canadian Institutes of Health Research (CIHR), will test needle-free vaccines developed to provide protection from SARS-CoV-2.
Led by Fiona Smaill and Zhou Xing, members of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) at McMaster, the multi-centre trial will evaluate the new vaccine in a broad study group, while also confirming safety.
Comments closed

